The mitochondria-targeting peptide SS-31 improved virtually every aspect of pulmonary arterial hypertension in mice — from blood pressure to fibrosis to DNA damage — by protecting cells at the mitochondrial level.
8+ pathways improvedSS-31 simultaneously improved oxidative stress, inflammation, calcium overload, apoptosis, fibrosis, hypoxia, DNA damage, and endothelial function in pulmonary hypertension
What the researchers found
The mitochondria-targeting antioxidant peptide SS-31 (2 mg/day IP for 60 days) significantly reduced right ventricular systolic blood pressure and lung injury in mice with TAC-induced pulmonary arterial hypertension. SS-31 simultaneously improved multiple disease pathways: it decreased oxidative stress (NOX-1/NOX-2), inflammation (MMP-9/TNF-α/iNOS), calcium overload (TRPC channels), apoptosis (BAX/caspase 3/PARP), fibrosis (Smad3/TGF-β), hypoxia signaling (HIF-1α), and DNA damage (γ-H2AX).
Conversely, SS-31 increased antioxidant proteins (HO-1/NQO-1/GR/GPx), anti-fibrotic markers (Smad1/5, BMP-2), small vessel number, and alveolar sacs — demonstrating comprehensive protection of lung tissue architecture and function.
Why it matters
Pulmonary arterial hypertension has limited treatment options and carries a poor prognosis. SS-31 (also known as elamipretide/Bendavia) is a remarkable peptide that selectively targets the inner mitochondrial membrane, protecting cells from oxidative damage at its source. This study shows SS-31 improves virtually every aspect of PAH pathology — from blood pressure to fibrosis to DNA damage — suggesting that mitochondrial dysfunction is a central driver of PAH and that targeting it with this peptide addresses the root cause rather than just symptoms.
The numbers in context
2 mg/day × 60 days · RVSBP significantly reduced · 8+ pathological pathways improved · Antioxidant proteins increased · Lung injury score improved · Muscularized vessels reduced
How the study worked
Adult male C57BL mice were divided into three groups: sham-operated controls, TAC-induced PAH, and TAC+SS-31 (2 mg/day intraperitoneal for 60 days). Right ventricular systolic blood pressure was measured on day 60. Heart and lung tissues were analyzed for oxidative stress, inflammation, calcium overload, apoptosis, fibrosis, hypoxia, DNA damage, and endothelial function markers via histological and biochemical examination.
Who was studied
Adult male C57BL mice in three experimental groups (sham, TAC, TAC+SS-31)
What this study cannot tell us
This is a mouse model study using TAC-induced PAH, which may not fully replicate the complex pathophysiology of human pulmonary hypertension. Only one dose of SS-31 was tested, so the optimal therapeutic dose is unknown. The 60-day treatment period is relatively short for a chronic disease. The mechanisms were characterized descriptively (biomarker changes) without detailed pathway analysis to determine which effects are primary versus secondary to mitochondrial protection.
How to read the evidence
This is a preclinical mouse model study with comprehensive biochemical and histological analysis. The breadth of markers examined strengthens the findings, but translation to human PAH requires clinical trials.
When this study was published
Published in 2016, this study contributed to the body of evidence supporting SS-31 (elamipretide) as a mitochondrial therapeutic. The peptide has since advanced through various stages of clinical development for other cardiovascular indications.
The bigger picture
SS-31 (elamipretide) is one of the most-studied mitochondria-targeting peptides, with clinical trials for heart failure and other conditions. This study adds pulmonary hypertension to its potential therapeutic portfolio and supports the broader concept that mitochondrial dysfunction underlies many cardiovascular diseases. If these results translate to humans, SS-31 could offer a fundamentally different approach to treating PAH — protecting mitochondria rather than just dilating blood vessels.
Questions still open
- Can SS-31’s benefits in mouse PAH be replicated in human pulmonary hypertension clinical trials?
- Is the comprehensive multi-pathway improvement driven primarily by mitochondrial protection, or does SS-31 have additional non-mitochondrial effects?
- Could SS-31 be combined with existing PAH medications for additive benefit?
Common questions
What is SS-31 and how does it target mitochondria?
What is pulmonary arterial hypertension?
Read the original research
Administration of antioxidant peptide SS-31 attenuates transverse aortic constriction-induced pulmonary arterial hypertension in mice.
Acta pharmacologica Sinica, 37(5), 589-603
Citation
Lu, Hung-I; Huang, Tien-Hung; Sung, Pei-Hsun; Chen, Yung-Lung; Chua, Sarah; Chai, Han-Yan; Chung, Sheng-Ying; Liu, Chu-Feng; Sun, Cheuk-Kwan; Chang, Hsueh-Wen; Zhen, Yen-Yi; Lee, Fan-Yen; Yip, Hon-Kan. (2016). Administration of antioxidant peptide SS-31 attenuates transverse aortic constriction-induced pulmonary arterial hypertension in mice.. Acta pharmacologica Sinica, 37(5), 589-603. https://doi.org/10.1038/aps.2015.162